Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Selective ploidy ablation, a high-throughput plasmid transfer protocol, identifies new genes affecting topoisomerase I-induced DNA damage.

Reid RJ, González-Barrera S, Sunjevaric I, Alvaro D, Ciccone S, Wagner M, Rothstein R.

Genome Res. 2011 Mar;21(3):477-86. doi: 10.1101/gr.109033.110. Epub 2010 Dec 20.

2.

Effects of camptothecin or TOP1 overexpression on genetic stability in Saccharomyces cerevisiae.

Sloan R, Huang SN, Pommier Y, Jinks-Robertson S.

DNA Repair (Amst). 2017 Nov;59:69-75. doi: 10.1016/j.dnarep.2017.09.004. Epub 2017 Sep 18.

PMID:
28961461
3.

SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage.

Mao Y, Sun M, Desai SD, Liu LF.

Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4046-51.

4.

Directed evolution to increase camptothecin sensitivity of human DNA topoisomerase I.

Scaldaferro S, Tinelli S, Borgnetto ME, Azzini A, Capranico G.

Chem Biol. 2001 Sep;8(9):871-81.

6.

Yeast Tdp1 and Rad1-Rad10 function as redundant pathways for repairing Top1 replicative damage.

Vance JR, Wilson TE.

Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13669-74. Epub 2002 Oct 4.

7.
8.

Enhanced CPT sensitivity of yeast cells and selective relaxation of Ga14 motif-containing DNA by novel Gal4-topoisomerase I fusion proteins.

Alessandri M, Beretta GL, Ferretti E, Mancia A, Khobta A, Capranico G.

J Mol Biol. 2004 Mar 19;337(2):295-305.

PMID:
15003448
9.

Camptothecin sensitivity is mediated by the pleiotropic drug resistance network in yeast.

Reid RJ, Kauh EA, Bjornsti MA.

J Biol Chem. 1997 May 2;272(18):12091-9.

10.

Genome-destabilizing effects associated with top1 loss or accumulation of top1 cleavage complexes in yeast.

Andersen SL, Sloan RS, Petes TD, Jinks-Robertson S.

PLoS Genet. 2015 Apr 1;11(4):e1005098. doi: 10.1371/journal.pgen.1005098. eCollection 2015 Apr.

11.

Engineered Saccharomyces cerevisiae strain for improved xylose utilization with a three-plasmid SUMO yeast expression system.

Hughes SR, Sterner DE, Bischoff KM, Hector RE, Dowd PF, Qureshi N, Bang SS, Grynaviski N, Chakrabarty T, Johnson ET, Dien BS, Mertens JA, Caughey RJ, Liu S, Butt TR, LaBaer J, Cotta MA, Rich JO.

Plasmid. 2009 Jan;61(1):22-38. doi: 10.1016/j.plasmid.2008.09.001. Epub 2008 Oct 26.

PMID:
18831987
12.

Defects in SUMO (small ubiquitin-related modifier) conjugation and deconjugation alter cell sensitivity to DNA topoisomerase I-induced DNA damage.

Jacquiau HR, van Waardenburg RC, Reid RJ, Woo MH, Guo H, Johnson ES, Bjornsti MA.

J Biol Chem. 2005 Jun 24;280(25):23566-75. Epub 2005 Apr 6.

13.

DNA topoisomerase-targeting antitumor drugs can be studied in yeast.

Nitiss J, Wang JC.

Proc Natl Acad Sci U S A. 1988 Oct;85(20):7501-5.

14.

Studying DNA topoisomerase I-targeted drugs in the yeast. Saccharomyces cerevisiae.

Woo MH, Vance JR, Bjornsti MA.

Methods Mol Biol. 2001;95:303-13. No abstract available.

PMID:
11089242
15.

Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants.

Knab AM, Fertala J, Bjornsti MA.

J Biol Chem. 1993 Oct 25;268(30):22322-30.

16.

Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine.

Benedetti P, Fiorani P, Capuani L, Wang JC.

Cancer Res. 1993 Sep 15;53(18):4343-8.

17.

Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin.

Eng WK, Faucette L, Johnson RK, Sternglanz R.

Mol Pharmacol. 1988 Dec;34(6):755-60.

PMID:
2849043
18.

Increased camptothecin toxicity induced in mammalian cells expressing Saccharomyces cerevisiae DNA topoisomerase I.

Hann C, Evans DL, Fertala J, Benedetti P, Bjornsti MA, Hall DJ.

J Biol Chem. 1998 Apr 3;273(14):8425-33.

19.
20.

Mitotic chromosome condensation in the rDNA requires TRF4 and DNA topoisomerase I in Saccharomyces cerevisiae.

Castaño IB, Brzoska PM, Sadoff BU, Chen H, Christman MF.

Genes Dev. 1996 Oct 15;10(20):2564-76.

Supplemental Content

Support Center